Center for Pharmaceutical Biotechnology and Department of Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, United States of America.
PLoS One. 2010 Sep 1;5(9):e12518. doi: 10.1371/journal.pone.0012518.
Progenitor cell therapies show great promise, but their potential for clinical applications requires improved storage and transportation. Desiccated cells stored at ambient temperature would provide economic and practical advantages over approaches employing cell freezing and subzero temperature storage. The objectives of this study were to assess a method for loading the stabilizing sugar, trehalose, into hematopoietic stem and progenitor cells (HPC) and to evaluate the effects of subsequent freeze-drying and storage at ambient temperature on differentiation and clonogenic potential. HPC were isolated from human umbilical cord blood and loaded with trehalose using an endogenous cell surface receptor, termed P2Z. Solution containing trehalose-loaded HPC was placed into vials, which were transferred to a tray freeze-dryer and removed during each step of the freeze-drying process to assess differentiation and clonogenic potential. Control groups for these experiments were freshly isolated HPC. Control cells formed 1450+/-230 CFU-GM, 430+/-140 BFU-E, and 50+/-40 CFU-GEMM per 50 microL. Compared to the values for the control cells, there was no statistical difference observed for cells removed at the end of the freezing step or at the end of primary drying. There was a gradual decrease in the number of CFU-GM and BFU-E for cells removed at different temperatures during secondary drying; however, there were no significant differences in the number of CFU-GEMM. To determine storage stability of lyophilized HPC, cells were stored for 4 weeks at 25 degrees C in the dark. Cells reconstituted immediately after lyophilization produced 580+/-90 CFU-GM ( approximately 40%, relative to unprocessed controls p<0.0001), 170+/-70 BFU-E (approximately 40%, p<0.0001), and 41+/-22 CFU-GEMM (approximately 82%, p = 0.4171), and cells reconstituted after 28 days at room temperature produced 513+/-170 CFU-GM (approximately 35%, relative to unprocessed controls, p<0.0001), 112+/-68 BFU-E (approximately 26%, p<0.0001), and 36+/-17 CFU-GEMM ( approximately 82%, p = 0.2164) These studies are the first to document high level retention of CFU-GEMM following lyophilization and storage for 4 weeks at 25 degrees C. This type of flexible storage stability would potentially permit the ability to ship and store HPC without the need for refrigeration.
祖细胞疗法显示出巨大的潜力,但要将其应用于临床,还需要改进储存和运输方式。在常温下储存干燥的细胞将比采用细胞冷冻和亚低温储存的方法具有更大的经济和实际优势。本研究的目的是评估一种向造血干/祖细胞(HPC)加载稳定糖海藻糖的方法,并评估随后的冷冻干燥和在常温下储存对分化和集落形成能力的影响。HPC 从人脐带血中分离出来,并使用一种称为 P2Z 的内源性细胞表面受体加载海藻糖。含有海藻糖负载 HPC 的溶液被放置在小瓶中,然后将小瓶转移到托盘冷冻干燥器中,并在冷冻干燥过程的每一步中取出,以评估分化和集落形成能力。这些实验的对照组是新鲜分离的 HPC。对照组细胞每 50 μL 形成 1450±230 CFU-GM、430±140 BFU-E 和 50±40 CFU-GEMM。与对照组细胞的值相比,在冷冻步骤结束时或在主干燥结束时取出的细胞没有观察到统计学差异。在二次干燥过程中,不同温度下取出的细胞的 CFU-GM 和 BFU-E 数量逐渐减少;然而,CFU-GEMM 的数量没有显著差异。为了确定冻干 HPC 的储存稳定性,将细胞在 25°C 黑暗中储存 4 周。冷冻干燥后立即重建的细胞产生 580±90 CFU-GM(约 40%,相对于未处理的对照,p<0.0001)、170±70 BFU-E(约 40%,p<0.0001)和 41±22 CFU-GEMM(约 82%,p=0.4171),而在室温下重建 28 天后的细胞产生 513±170 CFU-GM(约 35%,相对于未处理的对照,p<0.0001)、112±68 BFU-E(约 26%,p<0.0001)和 36±17 CFU-GEMM(约 82%,p=0.2164)。这些研究首次记录了在 25°C 下冷冻干燥和储存 4 周后 CFU-GEMM 的高保留率。这种灵活的储存稳定性有可能使 HPC 的运输和储存无需冷藏。